Institutional investors have a lot riding on ADMA Biologics, Inc. with 77 percent ownership
ADMA Stock | USD 21.47 0.29 1.37% |
About 66 percent of all ADMA Biologics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that a large number of traders are confidant. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
Key Insights Given the large stake in the stock by institutions, ADMA Biologics stock price might be vulnerable to...
Read at simplywall.st
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
ADMA Biologics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
MCRB | Seres Therapeutics | 15.58 | ||||
FATE | Fate Therapeutics | 5.68 | ||||
ATRA | Atara Biotherapeutics | 5.67 | ||||
ANTX | AN2 Therapeutics | 3.73 | ||||
PLRX | Pliant Therapeutics | 3.70 | ||||
STOK | Stoke Therapeutics | 3.06 | ||||
AKBA | Akebia Ther | 2.66 | ||||
ETNB | 89bio | 2.28 | ||||
CRBU | Caribou Biosciences | 2.02 | ||||
VXRT | Vaxart | 1.67 | ||||
PLX | Protalix Biotherapeutics | 1.18 | ||||
MDGL | Madrigal Pharmaceuticals | 0.65 | ||||
RCUS | Arcus Biosciences | 0.95 | ||||
ACLX | Arcellx | 1.14 | ||||
INMB | INmune Bio | 1.44 | ||||
IBIO | Ibio | 3.03 | ||||
ANEB | Anebulo Pharmaceuticals | 4.11 | ||||
BCRX | BioCryst Pharmaceuticals | 4.34 | ||||
SANA | Sana Biotechnology | 4.98 | ||||
TNXP | Tonix Pharmaceuticals | 5.00 | ||||
TFFP | Tff Pharmaceuticals | 5.88 | ||||
XFOR | X4 Pharmaceuticals | 8.11 | ||||
CDTX | Cidara Therapeutics | 8.38 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |